AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 312 min read$IQV

Cherofsky Keriann sold $137K of IQV

Cherofsky Keriann (See Remarks) sold 558 shares of IQVIA HOLDINGS INC. (IQV) at $245.21 ($0.14M total) on 2026-07-29.

Original reporting
SEC EDGAR · Cherofsky Keriann
Published Jul 31, 2026, 9:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$IQV
Neutral
low confidence
Mentioned
$IQV
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

Insider open-market sales can be interpreted as sentiment signals, but without additional company-specific information, the trading impact is typically limited.

02

Market read

A modest insider sale was disclosed via Form 4, offering limited incremental information for trading decisions.

03

What to watch

The article does not state whether the insider’s remaining holdings are part of a broader pattern, nor does it provide context on compensation, vesting, or prior sales frequency.

Relevance 4/10Novelty 3/10Timing: filed 2026-07-31, sale dated 2026-07-29

Background

The article is a SEC Form 4 insider transaction disclosure for IQVIA Holdings Inc.

Company-level read

Ticker impact

$IQVNeutralLow confidence
Context

IQVIA Form 4 shows officer Cherofsky Keriann sold 558 shares at $245.21 on 2026-07-29 for about $136.8K, after which she held 2,989 shares.

Expected impact

Likely negligible near-term price impact; any effect would be limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing is a primary-source Form 4, but the transaction value (~$137K) is modest relative to IQVIA’s market scale, and the article provides no accompanying corporate event, guidance, or legal/regulatory development.

Market effects

Sector

No sector read-through is provided beyond a single insider sale at a large healthcare/clinical research services company.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be driven by personal liquidity needs or tax planning rather than a bearish view, especially since the filing does not include any negative company-specific catalyst.

Key entities

  • issuer
    IQVIA Holdings Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Cherofsky Keriann

    Officer who sold 558 shares in an open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IQV insider trading history →

Related articles

AUG 30
$IQVHighAI 9/10

Will IQVIA’s Upgraded 2026 Guidance and Bookings Strength Change IQVIA Holdings' (IQV) Narrative

IQVIA Holdings (IQV) reported Q2 earnings that beat expectations, with adjusted earnings up 12.1% and revenue up 8.7% year over year. The company raised its 2026 guidance for revenue, adjusted EBITDA, and earnings, citing strong bookings and acquisitions. Management attributes the upgrade to broad-based demand and operational efficiency, including AI-driven initiatives like IQVIA.ai. The stock is projected to reach $20.4 billion in revenue and $2.0 billion in earnings by 2029, representing a 5%

simplywall.st2 min
AUG 9
$IQVMed

How IQVIA’s Medera Cardiac Gene Therapy Alliance and Raised 2026 Outlook Will Impact IQV (IQV) Investors

IQVIA Inc. said it raised full-year 2026 revenue guidance to US$17.28–US$17.48 billion, with Q3 outlook of US$4.32–US$4.39 billion, alongside reporting Q2 results and buyback activity. IQVIA also announced a collaboration with Medera Inc. on cardiac gene therapies and human-based drug discovery, linking IQVIA trial and platform capabilities to Medera programs.

simplywall.st6 min
AUG 4
$IQVMed

5 Insightful Analyst Questions From IQVIA’s Q2 Earnings Call

IQVIA reported Q2 CY2026 results with revenue of $4.37B versus $4.30B estimates and adjusted EPS of $3.15 versus $3.03, with adjusted EBITDA of $994M. Management cited 6% organic growth and strong net new bookings. Full-year revenue guidance was lifted to $17.38B and adjusted EPS to $12.90. Analysts discussed bookings, outsourcing, AI, M&A, and margins.

financialcontent.com6 min
AUG 2
Med

An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion

IQVIA Holdings CEO sold about $26.1 million of stock appreciation rights with a Feb 2027 expiration, while retaining a large share position, according to the filing and article. The company reported Q2 revenue up 8.7% to $4.37B, adjusted EPS up 12.1% to $3.15, and record clinical bookings of $3.15B, raising full-year guidance to $17.475B.

yahoo.com5 min